Account

Search results for: germany

Biosimilar Switching in Germany from March 15, 202...

New biosimilar switching regulations prioritise cost-effective options and discount agreements, imp...

Read more
Confidential rebates are raising concerns in Germa...

Proposed changes in Germany's pharma strategy suggest replacing publicly listed AMNOG rebates with c...

Read more
AML treatment Tibsovo earns key rating in Germany

Tibsovo (ivosidenib) has been granted a major additional benefit rating for its use as a first-line ...

Read more
To improve Germany’s attractiveness, confidentia...

Germany’s Health minister has announced that publicly listed AMNOG rebates could be replaced by co...

Read more
ISPOR Europe 2023: Evaluation and Reimbursement of...

Our study compares and contrasts the evaluation and reimbursement pathways for digital therapeutics ...

Read more
Germany’s Health Ministry Shifts Focus to Di...

Germany is reshaping its Ministry of Health to prioritize the prevention of diseases like cancer, de...

Read more
The EU Pharmaceutical package missed the mark in t...

EFPIA and VFA bosses state their concerns that the newly released EU Pharmaceutical Laws will furthe...

Read more
More clarity given on the proposed changes to comb...

The German government has released information regarding the 20% discounts to combination products e...

Read more
Germany – European joint assessment at deadlock ...

Germany's BPI and vfa advise that the implementation of the European Health Technology Assessment (E...

Read more
Developing scenario-based commercial assessments

Identification of current cost of oncology care treatment options.

Read more
Older

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch